1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries
Ping Gao(University of Science and Technology of China), Xinyong Liu(Shandong University of Traditional Chinese Medicine), Erik De Clercq(Rega Institute for Medical Research), Luis Menéndez‐Arias(Consejo Superior de Investigaciones Científicas), Jing Tan(Shandong University), Tianguang Huang(Shandong University), Zhongxia Zhou(Shandong University), Peng Zhan(Shandong University of Traditional Chinese Medicine), Jian Zhang(Shanxi Medical University), Lin Sun(Shandong University), Lingzi Zhang(Shandong University), Tong Zhao(China Pharmaceutical University), Christophe Pannecouque(Rega Institute for Medical Research)
Cited by 17
Related Papers
Metabolic reprogramming and epigenetic modifications on the path to cancer
|Protein & Cell|2021|737
Therapeutic strategies for COVID-19: progress and lessons learned
|Nature Reviews Drug Discovery|2023|671
Antiviral agents active against influenza A viruses
|Nature Reviews Drug Discovery|2006|666
Identification of a cellularly active SIRT6 allosteric activator
|Nature Chemical Biology|2018|272